Medical Xpress·3 min read·hard
Trial evaluates maternal vaccine to protect newborns from Group B Streptococcus
W
Wits University
✦AI Summary
A phase 1/2 clinical trial has demonstrated that Pfizer's investigational maternal vaccine for Group B Streptococcus is safe and effective at transferring antibodies to newborns. The study, led by Wits VIDA, highlights the potential to reduce neonatal sepsis and mortality.
edited by Lisa Lock , reviewed by Robert Egan
healthscience
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in